{"product_id":"collegiumpharma-bcg-matrix","title":"Collegium Pharmaceutical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuick snapshot: Collegium Pharmaceutical’s BCG Matrix shows which products are pulling their weight and which need tough choices — from Stars to Dogs. This preview teases quadrant placements and market momentum, but the full report gives the exact positioning, revenue drivers, and risk signals you can act on. Buy the complete BCG Matrix for quadrant-level recommendations, ready-to-use Word and Excel files, and a clear roadmap to decide where to invest, divest, or double down. Get it now and skip the guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBELBUCA (buprenorphine buccal film)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBELBUCA (buprenorphine buccal film), approved in 2015 and classified as DEA Schedule III, is positioned as a fast-growing chronic pain option with safer respiratory and abuse profiles versus full-agonist opioids. Its differentiated pharmacology is driving momentum and share gains among prescribers seeking lower-risk alternatives. Continued investment in access, clinician education, and specialty reach is needed to cement leadership. If the current uptake trend continues, BELBUCA can evolve into a significant cash engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXtampza ER (oxycodone ER, DETERx)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXtampza ER (oxycodone ER, DETERx) holds a leading share inside the abuse‑deterrent oxycodone niche with clear clinical positioning and FDA approval for its DETERx technology.\u003c\/p\u003e\n\u003cp\u003eAs payers, regulators, and prescribers continue shifting toward safer formulations, ongoing investment in clinical evidence, access wins, and patient support preserve Xtampza ERs frontline status.\u003c\/p\u003e\n\u003cp\u003eMaintain share now; as the abuse‑deterrent category stabilizes, Xtampza ER is positioned to transition into a durable cash cow for Collegium.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDETERx technology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDETERx is a proprietary abuse‑deterrent platform that underpins Xtampza ER (FDA approved 2016) and creates a moat by enabling tamper‑resistant oral formulations; the platform supports line extensions and next‑gen candidates as payers increasingly favor ADF labeling. Continued investment in clinical trials and HEOR evidence is required to drive formulary uptake and justify premium pricing. With recurring regulatory and market wins, DETERx can shift from a growth driver to a sustainable profit base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowing specialty pain footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGrowing specialty pain footprint: deep relationships in pain clinics and select primary care segments are translating to script momentum, with specialty pain scripts up ~20% year-over-year in 2024, driving improved market share in targeted channels.\u003c\/p\u003e\n\u003cp\u003eFocused call points shorten adoption cycles for differentiated therapies; continued investment in field force quality and targeted education is recommended to sustain gains.\u003c\/p\u003e\n\u003cp\u003eSustain share gains here so the channel becomes a durable engine for recurring specialty revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: ~20% YoY specialty script growth\u003c\/li\u003e\n\u003cli\u003eInvest: field force training, targeted HCP education\u003c\/li\u003e\n\u003cli\u003eOutcome: faster adoption, durable channel-driven share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormulary access wins (ADF category)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFormulary access wins in the ADF category drive volume and stickiness for Collegium, as preferred-tier placement plus step edits that steer patients to safer ADF options are primary levers for share capture; industry analyses in 2024 showed payers increasingly favoring ADF pathways, boosting formulary-protected brands' prescription longevity. Sustained contracting and real-world outcomes data are required to defend and compound access into cash generation over time.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreferred tiers + step edits = higher initiation and persistence\u003c\/li\u003e\n\u003cli\u003eOutcomes data needed to retain slot and justify pricing\u003c\/li\u003e\n\u003cli\u003eAccess retention compounds into recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eADF pain leaders gain as payers favor safer Rx; specialty scripts +\u003cstrong\u003e20%\u003c\/strong\u003e YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBELBUCA and Xtampza ER are Stars: high-growth, market-leading ADF pain assets gaining share as payers favor safer formulations. Specialty scripts grew ~20% YoY in 2024, driving access and formulary wins. Continued investment in HEOR, field force, and access is required to sustain growth toward cash‑cow status.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eApproval\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eBCG role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBELBUCA\u003c\/td\u003e\n\u003ctd\u003e2015\u003c\/td\u003e\n\u003ctd\u003eSpecialty scripts +20% YoY\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza ER\u003c\/td\u003e\n\u003ctd\u003e2016\u003c\/td\u003e\n\u003ctd\u003eLeading ADF oxy niche\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG Matrix review of Collegium’s product portfolio with strategic actions for Stars, Cash Cows, Question Marks and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Collegium BCG Matrix that simplifies portfolio decisions — clean, printable view for quick C-level sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNUCYNTA ER (tapentadol ER)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNUCYNTA ER (tapentadol ER) is an established brand with meaningful share in the mature chronic pain segment, serving a market where chronic pain affects about 20% of US adults (CDC). Predictable demand and efficient promotion requirements support solid gross margins and low marketing churn. Focus on adherence, renewals, and selective contracting preserves recurring revenue. Cash flow from NUCYNTA ER funds investments in faster-growing portfolio areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNUCYNTA IR (tapentadol IR)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNUCYNTA IR (tapentadol IR) sits in a stable acute pain niche with a known prescriber base and mature channel dynamics, delivering dependable revenue with low promotional and R\u0026amp;D spend requirements. Limited category growth constrains upside, but optimizing product mix, sample deployment, and pull-through in favorable access pockets preserves margin contribution. It remains a steady payer of the company’s bills and a cash-generating backbone for near-term operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-cycle chronic pain prescriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLong-cycle chronic pain prescriptions, anchored by products like Xtampza ER (FDA approved 2016), function as cash cows: chronic pain affects 20.4% of US adults (CDC 2019), driving recurring refills and lower acquisition costs over time. Mature prior-authorization and patient-support workflows sustain continuity and adherence. Small efficiency tweaks in fulfillment and coding can meaningfully lift margins. Milk predictability while reallocating growth capital to higher-upside assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished distribution and trade relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium leverages established wholesaler and pharmacy networks tuned to its branded pain portfolio, enabling minimal incremental investment to maintain service levels and shelf presence. Using 2024 U.S. pharmacy coverage of roughly 21,000 outlets and broad wholesaler reach, the company can use data-sharing and inventory discipline to shave DSO and squeeze working-capital gains. The portfolio quietly throws off cash without soaking up corporate resources.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ewholesaler reach: broad national coverage\u003c\/li\u003e\n\u003cli\u003epharmacies: ~21,000 U.S. outlets (2024)\u003c\/li\u003e\n\u003cli\u003ecapex: minimal to maintain shelf presence\u003c\/li\u003e\n\u003cli\u003ecash flow: steady operational cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal-world evidence and HEOR library\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReal-world evidence and HEOR library drive payer renewals and shorten re-justification cycles, with industry 2024 analyses showing RWE-supported submissions achieve ~25% higher renewal success and shorten prior authorization duration by ~30%, protecting Collegium’s margin while avoiding heavy promotional spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepurpose across brands: low incremental cost, ~10–20% savings vs new studies\u003c\/li\u003e\n\u003cli\u003eKeep lean: minimal ongoing spend, high ROI\u003c\/li\u003e\n\u003cli\u003eReliable leverage: protects gross margin and payer access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eER chronic-pain: steady cash flow, RWE renewals \u003cstrong\u003e≈+25%\u003c\/strong\u003e, PA time \u003cstrong\u003e≈−30%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNUCYNTA ER\/IR and Xtampza ER act as cash cows: stable demand (chronic pain 20.4% US adults), low promo\/R\u0026amp;D, steady gross margins and predictable cash to fund growth. Efficient wholesaler\/pharmacy coverage (~21,000 outlets in 2024) and RWE-driven renewals (≈+25% success, −30% PA time) protect margins with minimal capex.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic pain prevalence\u003c\/td\u003e\n\u003ctd\u003e20.4% (CDC)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies (2024)\u003c\/td\u003e\n\u003ctd\u003e~21,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE renewal uplift\u003c\/td\u003e\n\u003ctd\u003e≈+25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePA time reduction\u003c\/td\u003e\n\u003ctd\u003e≈−30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003eMinimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final Collegium Pharmaceutical BCG Matrix you'll receive after purchase. No watermarks or demo text—just a fully formatted, analysis-ready report built for strategic decisions. After buying, the exact same document is instantly downloadable and editable. Use it in decks, planning sessions, or client presentations with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164108665209,"sku":"collegiumpharma-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/collegiumpharma-bcg-matrix.png?v=1762726012","url":"https:\/\/portersfiveforce.com\/products\/collegiumpharma-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}